News – Access Vaccines

9.09.2026 – Groundbreaking Phase 3 Trial Success on Personalized Cancer Vaccines

Merck and Moderna’s personalized mRNA cancer vaccine, intismeran autogene, significantly extended recurrence-free survival when combined with Keytruda in a phase 3 trial involving 1,137 patients with high-risk melanoma. The treatment also improved distant metastasis-free survival, showed no new safety concerns, and is now being evaluated for potential regulatory submissions. The results mark a major step forward for individualized cancer vaccines and could accelerate the development of personalized treatments for solid tumors.

8.15.2026 – Access Vaccines Sanofi Members will earn the Lowest National Pricing on Sanofi Vaccines – starting 9.1.26

Members must be enrolled in Mainline Tier 1 to receive decreased pricing. Accounts ordering Infant RSV, must use Beyfortus in order to be elegible to receive Tier 1 discounts. Tier 1 discounts lower all Sanofi vaccines to the lowest national pricing available in the market. Tier 2 Discounts available for non Beyfortus users as well.

Contact your Access Vaccines representative today to make sure you’re clinic is enrolled correctly to take advantage of these upcoming discounts.

7.1.2026 – Access Vaccines members earn increased discounts on Prevnar 20

Starting July 1, 2026 – Access Vaccines Pfizer Members Receive Increase on Prevnar 20 Discounts, members earn up to 26% off List Price.

Enroll in the Access Vaccines Pfizer Discount Program to take advantage of these increased savings. Members fully aligned to Pfizer’s Portfolio of Vaccines earn an additional 2% off all Pfizer Brands by enrolling in the Access Vaccines Pfizer Portfolio Discount Program.

6.19.2026 – Access Vaccines member earn discounts on all GSK Vaccines including Shingrix.

A new study found a potential link between Shingrix and a lower dementia risk.

A large-scale study of 1.5 million Medicare beneficiaries found that the two-dose Shingrix shingles vaccine is linked to a 33% lower risk of dementia in adults over age 65.
The recombinant zoster vaccine was specifically associated with a 28% reduced risk of Alzheimer’s disease and a 33% lower risk of vascular dementia compared to unvaccinated individuals.
While the findings suggest a significant correlation between shingles vaccination and brain health, researchers note that further clinical studies are required to prove a direct causal association.
The CDC currently recommends that adults aged 50 and older receive the two-dose Shingrix series to prevent painful shingles complications, with this potential cognitive protection serving as a secondary benefit.

4.29.2026 – CDC Restores Official U.S. Immunization Schedules to July 2, 2025, Versions to Comply with March 16 Court Order

In compliance with the March 16 federal court ruling in American Academy of Pediatrics v. Kennedy, CDC restored its official child and adolescent immunization schedule and its official adult immunization schedule to the July 2, 2025, versions. These versions reflect the decisions of the ACIP through its April 2025 meeting, before the replacement of those 17 members with new members in June 2025. The appointments of the new members and their subsequent decisions were stayed by the court. Some CDC web pages are still being updated to reflect the change.

With the July 2025 schedules restored, routine ACIP recommendations are once again in effect for hepatitis A, hepatitis B (including routine birth dose), influenza, meningococcal ACWY, and rotavirus vaccines, as well as routine 2- or 3-dose HPV vaccination (depending on age at initiation). Once again, MMRV is an option on the schedule for children younger than age 4 years when preferred by parents, including VFC-eligible children.

For more information, see the Common Health Coalition’s 2-page summary of the AAP v. Kennedy Ruling and what it means for clinicians and families.

4.17.2026 – Access Vaccines member who are fully aligned to Pfizer’s Portfolio of Vaccines now earn an additional 2% off all indications when compared to the the Pfizer Select Program.

Prevnar Select: 21% off list price
Prevnar Portfolio: 23% off list price

Trumenba Select: 29% off list price
Trumenba Portfolio: 31% off list price

Abrsyvo Select: 14% off list price
Abrysvo Portfolio: 16% off list price

COVID Select: 46 – 48% off list price
COVID Portfolio: 48 – 50% off list price

Portfolio Contract Requirement:

80% market share requirment for all Pfizer brands, where applicable, clinics must purchase Pfizer brand for each indication used at clinic.

New pricing effective 4/1/26 for both Pfizer Select and Pfizer Portfolio members.

4.9.2026 – Access Vaccines Members Save on Infant RSV Brands

All Access Vaccines members are eligible to enroll in an Infant RSV discount Program. Last RSV season only 50% of newborns were protected against Infant RSV. Protect your newborn patients by vaccinating against Infant RSV.

Help protect your newborn patients this RSV sesaon by enrolling in an Access Vaccines Infant RSV Disocunt Program.

Enroll Today and Save on Your Preferred Infant RSV Brand.

2.09.2026 – Press Release: Sanofi completes the acquisition of Dynavax

Sanofi today announced that it has completed theacquisition of Dynavax Technologies Corporation (Dynavax). The acquisition includes Dynavax’s adult hepatitis B vaccine HEPLISAV-B, which is currently marketed in the US and is differentiated by its two-dose regimen over one month. It also includes Dynavax’s shingles vaccine candidate (Z-1018), which is currently in phase 1/2 studies, and additional vaccine pipeline projects.

What this means for Access Vaccines Members? All members enrolled for discounts will receive discounted member pricing on Dynavax vaccines.

1.26.2026 – 2026/27 Flu Prebook is Now Open

The prebook period for Access Vaccines members for the 2026/27 Flu Season has officially started. Now is the time to reserve your doses. Access Vaccines members have the choice between all brands of flu, at the lowest national prices for each brand:

Seqirus:
– Flucelvax (6+ months) *cell-based
– FluAd (65+ years)

Sanofi:
– Fluzone (6+ months)
– Flublok (18+ years)
– Fluzone High Dose (65+ years)

GSK:
– FluLaval (6+ months)
– Fluarix (6+months)

AstraZeneca:
– FluMist (2-49 years)

*all brands for the 2026/27 flu season are of Trivalent formulation*

Protect your patients this flu season and enroll your clinic in an Access Vaccines Flu Discount Program for the best terms and lowest pricing in the market.

1.22.2026 – Resource: Childhood Vaccines: Five things parents should know

As long-held pediatric vaccination protocols become a topic of national discourse, a Stanford Medicine infectious disease specialist shares his insights. With the changing landscape surrounding vaccines, learning from all perspectives can help us all identify, understand and address concerns surrounding vaccines.

“Pediatric clinicians have a key role to play in shedding light on the issue. It starts with listening carefully to parents’ questions and input, according to Seth Hoffman, MD, an infectious disease specialist at Stanford Medicine and a member of the Stanford Maternal and Child Health Research Institute.”

1.20.2026 – GSK’s Shingrix Now Available in Pre-Filled Syringe

Starting 2/1/26 GSK’s Shingrix is now available to all Access Vaccines GSK members in PFS.

ACIP and CDC recommend vaccination of the following people to prevent shingles and post-herpetic neuralgia, the chronic pain that may linger long after the acute shingles rash resolves:
– All adults age 50 years and older who have not received Shingrix
– Adults age 19 years and older with a weakened immune system because of disease or treatments

Access Vaccines Members save up to: 9% off list (20$+ off per dose).

1.6.2026 – Fact Checked: U.S. Vaccine Recommendations are Appropriate for Children in the United States

There is robust evidence to support the safety, effectiveness and necessity of U.S. vaccine recommendations. Some public figures have falsely implied that the number of recommended vaccines for children in the United States could be linked to chronic health conditions or autism and have called for re-testing proven immunizations. Others have claimed that the U.S. childhood vaccine schedule is unsafe or unnecessary because the United States recommends more routine vaccines than some countries, like Denmark. The truth is that while vaccine guidance is largely similar across developed countries, it may differ by country due to different disease threats, population demographics, health systems, costs, government structures, vaccine availability, and programs for vaccine delivery.

12.10.2025 – New Study Suggests Shingles Vaccine Could Slow Dementia

For those living with dementia, new study suggests shingles vaccine could slow the disease. A new analysis of a vaccination program in Wales found that the shingles vaccine not only appeared to lower new dementia diagnoses by 20%, it also helped those who already have the disease.

Access Vaccines members save over 6% off list price on Shingrix when enrolled in the Access Vaccines GSK Arexvy Tier Discount Program – which provides increased discounts on Shingrix.

10.1.2025 – Access Vaccines Members Receive Increased Discounts on all Brands of COVID

The COVID season is fast approaching and with the recent ACIP vote allowing all patients who are at-risk or who’s doctor recommends them to to receive COVID immunizations – be prepared to protect your patients against this new strain.

All Access Vaccines members are eligible to receive discounts on their preferred brand of COVID.

Pfizer mRNA: 8-22% off
Moderna mRNA: 31-35% off
Sanofi Traditional Protein Based: 29% off

7.4.2025 – In-Season Flu Doses Available at Discounted Pricing for Access Vaccines Members

Flu season is upon us and ramping up, Access Vaccines offers all our members discounts on all brands of Flu vaccines. Protect your patients against the flu with updated flu vaccines for the 2025-26 season. Prior to ordering your in-season doses, make sure you are enrolled in the correct Access Vaccines Flu Discount Programs to receive discounted member pricing on your in-season orders.

– Seqirus: doses available and ready to ship
– Sanofi: doses available and ready to ship
– GSK: waitlist
– FluMist: doses available and ready to ship

6.25.25 – New Discount Program Available for Pfizer: Pfizer Portfolio Program

Pfizer Portfolio Program: for accounts utilizing Pfizer’s portfolio of vaccines, earn an additional 2% off all brands through this new tier of discount with Pfizer.

2% Additional Discount*:
– Prevnar: 16.5% total discount
– Trumenba: 29% total discount
– COVID: 12+yrs: 26% total discount & 6mo-12yr: 12% total discount
– Abrysvo: 14% total discount

*2% Additional Discount: applied in addition to to already discounts Select Pfizer Member pricing, extra 2% applied in addition to 2% Prompt Pay.

Eligible Members: must purchase more than 80% market share for all Pfizer products (if administered).

Start Date: July 1, 2025